trivalent covid-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 10, 2022 (NCT05433272)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05593042 | Phase 2 | Oct 31, 2022 | China National Pharmaceutical Group, Pontificia Universidad Catolica de Chile |
| NCT05433272 | Phase 3 | Aug 10, 2022 | China National Pharmaceutical Group, Sinovac Biotech Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China National Pharmaceutical Group | For profit | 2 | 0 | 2 | 2022 |
| Pontificia Universidad Catolica de Chile | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Sinovac Biotech Co., Ltd | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1